BOTHELL, Wash. (AP) ¿ Development-stage biotechnology company Seattle Genetics Inc. said Thursday its third-quarter loss narrowed on higher revenue from partnerships.

The company lost $19.8 million, or 21 cents per share, compared with a loss of $21.8 million, or 27 cents per share, during the same period a year prior. Revenue rose 44 percent to $11.6 million from $8.1 million.

Analysts polled by Thomson Reuters expected a loss of 25 cents per share on revenue of $9.4 million.

The company's key partnership is with Genentech Inc., now part of Roche. The companies are developing potential cancer treatments.

Shares of Seattle Genetics rose 12 cents to close at $9.85.
Copyright 2009 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

If you liked this article you might like

What's Behind the Surge in Energy Stocks

Hillary Clinton Says Prosecuting Individuals is Key to Wall Street Reform